ABSTRACT
As the COVID-19 pandemic evolves, human milk banks worldwide continue to provide donor human milk to vulnerable infants who lack access to mother’s own milk. Under these circumstances, ensuring the safety of donor human milk is paramount, as the risk of vertical transmission of SARS-CoV-2 is not well understood. Here, we investigate the inactivation of SARS-CoV-2 in human milk by pasteurisation, and the stability of SARS-CoV-2 in human milk under cold storage (freezing or refrigeration). Following heating to 63°C or 56°C for 30 minutes, SARS-CoV-2 replication competent (i.e. live) virus was undetected in both human milk and the control medium. Cold storage of SARS-CoV-2 in human milk (either at 4°C or - 30°C) did not significantly impact infectious viral load over a 48 hour period. Our findings demonstrate that SARS-CoV-2 can be effectively inactivated by Holder pasteurisation, and confirm that existing milk bank processes will effectively mitigate the risk of transmission of SARS-COV-2 to vulnerable infants through pasteurised donor human milk.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No funding was secured for this study.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This project was approved by the Australian Red Cross Lifeblood Human Research Ethics Committee (Clifford 27042020).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵# joint senior authors
Conflict of Interest Disclosures: The authors have no conflicts of interest to disclose.
Funding/support: No funding was secured for this study.
Mr Walker designed the study, collected the data, analyzed the data, created the figure, drafted, and critically reviewed and revised the manuscript.
Dr Clifford conceptualized the study, designed the study, drafted, and critically reviewed and revised the manuscript.
Dr Bansal designed the study, and reviewed and revised the manuscript.
Drs Ospina Stella and Turville did critical work to prepare the laboratory to conduct this research, assisted in data collection, and reviewed the manuscript.
Dr Stelzer-Braid collected the data, analyzed the data, and reviewed the manuscript.
Dr Klein designed the study, drafted the initial manuscript, and critically reviewed and revised the manuscript.
Professor Rawlinson conceptualized the study, coordinated and supervised data collection, and critically reviewed and revised the manuscript.
All authors approved the final manuscript as submitted and agree to be accountable for all aspects of the work.
Data Availability
The data that support the findings of this study are available from the corresponding author (WR), upon reasonable request.
Abbreviations
- SARS-CoV-2
- severe acute respiratory syndrome coronavirus 2
- COVID-19
- coronavirus disease 2019
- MEM
- minimum essential medium
- TCID50
- 50% tissue culture infectious dose
